Jim Simons Travere Therapeutics, Inc. Transaction History
Renaissance Technologies LLC
- $70.6 Billion
- Q3 2025
A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 1,752,114 shares of TVTX stock, worth $60.4 Million. This represents 0.06% of its overall portfolio holdings.
Number of Shares
1,752,114
Previous 2,495,114
29.78%
Holding current value
$60.4 Million
Previous $36.9 Million
13.4%
% of portfolio
0.06%
Previous 0.05%
Shares
20 transactions
Others Institutions Holding TVTX
# of Institutions
269Shares Held
100MCall Options Held
2.36MPut Options Held
955K-
Janus Henderson Group PLC London, X010.6MShares$366 Million0.12% of portfolio
-
Black Rock Inc. New York, NY7.64MShares$264 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY6.72MShares$232 Million2.47% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.61MShares$228 Million0.0% of portfolio
-
Macquarie Group LTD Australia, C34.98MShares$172 Million0.14% of portfolio
About Travere Therapeutics, Inc.
- Ticker TVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 64,173,600
- Market Cap $2.21B
- Description
- Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...